BI-D1870 RSK Inhibitor II, also known as BI-D1870 CAS: 501437-28-1, is a chemical compound that has gained significant attention in recent years for its potential health benefits. This product is primarily known as an inhibitor of the ribosomal S6 kinase (RSK) pathway, which may have implications for the treatment of various diseases. In this article, we will explore the chemical properties of BI-D1870 RSK Inhibitor II, its potential health benefits, safety considerations, and dosing information.
The chemical name for BI-D1870 RSK Inhibitor II is 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-methyl-1H-imidazol-2-yl)urea.
The molecular formula of BI-D1870 RSK Inhibitor II is C21H26N6O.
The molecular weight of BI-D1870 RSK Inhibitor II is 382.47 g/mol.
The CAS number for BI-D1870 RSK Inhibitor II is 501437-28-1.
Top ten keywords from Google and Synonyms Synonym:
Health benefits of this product:
BI-D1870 RSK Inhibitor II has been found to have a variety of potential health benefits. One of the most studied applications of this compound is in the treatment of cancer. Specifically, BI-D1870 may be effective in treating breast cancer. Studies have shown that BI-D1870 can inhibit the growth of breast cancer cells by blocking the activity of RSK, a key component of the MAP kinase pathway.
In addition to cancer treatment, BI-D1870 RSK Inhibitor II may also have potential in the treatment of other diseases related to cell signaling and protein synthesis. These conditions include neurodegenerative disorders such as Alzheimer's disease.
BI-D1870 RSK Inhibitor II works by inhibiting the activity of the RSK enzyme. The RSK enzyme plays a critical role in regulating many cellular processes, including protein synthesis, cell survival, and apoptosis. By inhibiting this enzyme, BI-D1870 may be able to influence these processes and potentially affect the development and progression of various diseases.
The precise mechanism of action of BI-D1870 RSK Inhibitor II is not well understood, but it is believed to work by binding to and inhibiting the activity of the RSK enzyme.
BI-D1870 RSK Inhibitor II is generally considered to be safe when used as directed. However, as with any medication or supplement, there is some risk of side effects. It is important to consult with a healthcare provider before using BI-D1870 RSK Inhibitor II, especially if you have any underlying medical conditions or are taking other medications.
Some potential side effects of BI-D1870 RSK Inhibitor II include nausea, vomiting, fatigue, and diarrhea. More serious side effects may include liver toxicity and blood disorders. If you experience any of these symptoms or other severe side effects, you should seek medical attention immediately.
The optimal dosage of BI-D1870 RSK Inhibitor II will depend on the specific application and the individual's needs. It is important to follow the dosing instructions provided by a healthcare provider or on the product label. In general, doses of BI-D1870 RSK Inhibitor II in the range of 10-20 mg/kg per day have been used in animal studies.
BI-D1870 RSK Inhibitor II is a promising compound with potential health benefits in the treatment of cancer and neurodegenerative diseases. Its mechanism of action through the inhibition of the RSK pathway is a promising avenue for new drug therapies. While generally safe, it is important to consult with a healthcare provider before using BI-D1870 RSK Inhibitor II and to follow dosing instructions carefully. Further research is needed to fully understand the potential benefits and risks of this compound